4basebio PLC

Equities

4BB

GB00BMCLYF79

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:09 02/07/2024 BST			5-day change	1st Jan Change
1,550 ^GBX	0.00%		0.00%	+127.94%

06-28	4Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board	CI
06-05	4basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2023	CI

4Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board

June 28, 2024 at 03:45 pm

4basebio PLC announced that Hansjörg Plaggemars, a non-executive director, requested to step down from the board due to other business commitments which the board has accepted with immediate effect. The board would like to thank Mr. Plaggemars for his contribution to the Company.

Latest news about 4basebio PLC

4Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board	06-28	CI
4basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2023	06-05	CI
4basebio to supply synthetic DNA for mRNA vaccine program	04-10	AN
4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program	04-10	CI
4basebio updates markets on "key milestone" with client	03-21	AN
Alpha Real Trust says in "robust" financial shape	03-01	AN
4basebio wins DNA supply contract to support RNA therapies	03-01	AN
4basebio Wins Synthetic DNA Supply Tender from CPI	03-01	MT
4basebio interim loss widens as research costs increase	21/09/23	AN
4basebio PLC Reports Earnings Results for the Half Year Ended June 30, 2023	21/09/23	CI
4basebio PLC Receives A Grant from the Bill & Melinda Gates Foundation to Advance the Development Program of Thermostable Nucleic Acid Based Vaccines	01/08/23	CI
4basebio PLC and Neomatrix Announce Product Supply Agreement	25/05/23	CI
4basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2022	11/05/23	CI
4basebio PLC Announces Further Expansion of Its UK Facilities	03/04/23	CI
4basebio PLC Reports Earnings Results for the Half Year Ended June 30, 2022	30/09/22	CI
4basebio Teams Up With Universities to Research Neurofibromatosis Treatment	10/06/22	MT
4basebio PLC Announces Collaboration with University of Alabama and Teesside University	10/06/22	CI
4basebio PLC Reports Earnings Results for the Full Year Ended December 31, 2021	09/05/22	CI
4basebio PLC Announces Joint Development Agreement with Heqet Therapeutics	27/04/22	CI
4basebio PLC Announces the Expansion of its Synthetic DNA Product Offering	23/03/22	CI
4basebio Completes First Phase Of Synthetic DNA Business Development	15/02/22	MT
4basebio PLC Appoints Mark Cooper as Head of Manufacturing	15/02/22	CI
4basebio Unit Partners With eTheRNA To Study Linear DNA For mRNA Production	18/01/22	MT
4Basebio Discovery Limited and Etherna Immunotherapies Enters into Strategic Research Collaboration	18/01/22	CI
4basebio : To Develop DNA Manufacturing Facility	28/09/21	MT

Chart 4basebio PLC

Duration

Period

More charts

Company Profile

4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.

Sector

Biotechnology & Medical Research

Calendar

26/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
4BASEBIO PLC	+127.94%	251M
MODERNA, INC.	+17.72%	44.44B
IQVIA HOLDINGS INC.	-10.33%	37.99B
LONZA GROUP AG	+37.55%	37.75B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	30.78B
CELLTRION, INC.	-8.44%	27.38B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.17B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.15B
MEDPACE HOLDINGS, INC.	+31.93%	12.59B
BIO-TECHNE CORPORATION	-7.67%	11.28B

Other Biotechnology & Medical Research

4basebio PLC

Equities

4BB

GB00BMCLYF79

Biotechnology & Medical Research

4Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board

Latest news about 4basebio PLC

Chart 4basebio PLC

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research